RE:RE:RE:RE:RE:Immmusafe website is back on line!…$$$ Improved understanding of key biomarkers has provided new, noninvasive ways to measure the earliest, asymptomatic stages of neurodegenerative disease. Some of the most commonly used biomarkers correlated to changes in cognitive health and AD include neurofilament light chain (NfL) and multiple isoforms of phosphorylated tau (pTau): 181, 217 and 231. These biomarkers have gained prominence as the definition of AD has shifted more towards a biological one. In early 2018, the FDA expanded what it recognized as acceptable endpoints in AD trials and would allow the use of response and monitoring biomarkers for the disease. The combination of new biomarkers and acceptance of their use in pivotal trials opens the doors for a more efficient approach to developing a therapy for AD.
https://www.linkedin.com/pulse/promis-bcni-team-up-ad-test-john-vandermosten
Note; FDA has "expanded" what is a Bio Marker